Dake Benjamin T's Form 4 filing
Jade Biosciences, Inc. (JBIO) · filed Jun 8, 2023
- Accession no.
- 0001415889-23-009448
- Filed
- Jun 8, 2023
- Trade date
- Jun 6, 2023
- Filing delay
- 2 days
- Rule 10b5-1 plan
- Checked
This filing lists 4 non-derivative transactions and 4 derivative transactions. Open-market sales total $167.4K. It was filed 2 days after the trade.
Reporting owners
A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.
| Owner | Relationship to the company |
|---|---|
| Dake Benjamin TCIK 0001869248 | Officer (SEE REMARKS) |
Non-derivative securities (Table I)
Acquisitions and disposals of common stock and similar shares, one row per line on the filing.
| Trade date | Security | Transaction | Shares | Price | Value | Shares after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| Jun 6, 2023 | Common Stock | MOption exerciseAcquired | +2,412 | $1.74 | +$4,196.88 | 3,703 | Direct | |
| Jun 6, 2023 | Common Stock | MOption exerciseAcquired | +7,871 | $2.14 | +$16,843.94 | 11,574 | Direct | |
| Jun 6, 2023 | Common Stock | SSaleDisposed | −10,268 | $16.28F2 | −$167,163.04 | 1,306 | Direct | |
| Jun 6, 2023 | Common Stock | SSaleDisposed | −15 | $16.98 | −$254.7 | 1,291 | Direct |
Derivative securities (Table II)
Options, warrants, restricted stock units and similar. Shares are the underlying shares; price and value are for the derivative itself, and the holding after is in derivative units.
| Trade date | Security | Transaction | Underlying shares | Unit price | Value | Held after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| Jun 6, 2023 | Common Stock | MOption exerciseDisposed | −905 | $0.00 | $0 | 6,339 | Direct | |
| Jun 6, 2023 | Common Stock | MOption exerciseDisposed | −1,507 | $0.00 | $0 | 21,095 | Direct | |
| Jun 6, 2023 | Common Stock | MOption exerciseDisposed | −1,018 | $0.00 | $0 | 22,405 | Direct | |
| Jun 6, 2023 | Common Stock | MOption exerciseDisposed | −6,853 | $0.00 | $0 | 164,461 | Direct |
Footnotes and remarks
Livermore keeps the footnotes that transaction prices refer to, all footnotes of amendments (Form 4/A) and the filing's remarks. Other footnotes, such as how indirect holdings are held or the details of a trading plan, are only in the original on SEC EDGAR.
- F2
The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $15.84 to $16.82, inclusive. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request.
Referenced by the price of 1 transaction in Table I.
Remarks
Officer Title: President, Chief Operating Officer and Secretary